Profile data is unavailable for this security.
About the company
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
- Revenue in USD (TTM)41.00k
- Net income in USD-82.59m
- Incorporated2000
- Employees72.00
- LocationChimerix Inc2505 Meridian Parkway, Suite 100DURHAM 27713United StatesUSA
- Phone+1 (919) 806-1074
- Fax+1 (919) 806-1146
- Websitehttps://www.chimerix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boundless Bio Inc | -100.00bn | -100.00bn | 79.45m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -53.37m | 80.74m | 54.00 | -- | 1.14 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 80.83m | 34.00 | -- | 0.5203 | -- | 21.01 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 80.97m | 47.00 | -- | 2.03 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -65.10m | 81.28m | 63.00 | -- | 0.3822 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Chimerix Inc | 41.00k | -82.59m | 81.52m | 72.00 | -- | 0.4682 | -- | 1,988.25 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 81.89m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 81.99m | 405.00 | -- | 1.42 | -- | 4.37 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Cidara Therapeutics Inc | 46.38m | -36.47m | 82.63m | 69.00 | -- | -- | -- | 1.78 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Instil Bio Inc | 0.00 | -123.32m | 83.25m | 49.00 | -- | 0.4045 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
| Bioatla Inc | 0.00 | -119.24m | 83.72m | 65.00 | -- | 1.68 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Beyondspring Inc | 1.75m | -21.03m | 83.82m | 35.00 | -- | -- | -- | 47.87 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 83.93m | 18.00 | -- | 2.12 | -- | 11,990.38 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 8.80m | 9.82% |
| Monaco Asset Management SAMas of 31 Mar 2024 | 4.38m | 4.88% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.32m | 4.82% |
| Armistice Capital LLCas of 31 Mar 2024 | 2.26m | 2.53% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 2.17m | 2.43% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.85m | 2.07% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.58m | 1.76% |
| Vestal Point Capital LPas of 31 Mar 2024 | 1.40m | 1.56% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.16m | 1.29% |
| Millennium Management LLCas of 31 Mar 2024 | 1.09m | 1.22% |
